Brilinta Clinical Experience Investigation

  • STATUS
    Recruiting
  • End date
    Mar 30, 2028
  • participants needed
    1750
  • sponsor
    AstraZeneca
Updated on 21 June 2021
Investigator
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (6.1 mi away) Contact
+31 other location

Summary

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase.

  1. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc.
  2. Profile and incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI
  3. Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke)
  4. Factors which may affect safety or efficacy of ticagrelor

Details
Condition Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction, Acute Coronary Syndrome, Old Myocardial Infarction
Clinical Study IdentifierNCT03212287
SponsorAstraZeneca
Last Modified on21 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients treated with BRILINTA for ACS or OMI, which is the indication of the drug

Exclusion Criteria

\-
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note